益气活血法干预脓毒症相关心功能障碍的临床研究

注册号:

Registration number:

ChiCTR2500109244 

最近更新日期:

Date of Last Refreshed on:

2025-09-16 08:49:06 

注册时间:

Date of Registration:

2025-09-16 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

益气活血法干预脓毒症相关心功能障碍的临床研究

Public title:

Clinical study of the intervention of Yiqi Huoxue therapy in sepsis-related cardiac dysfunction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

益气活血法干预脓毒症相关心功能障碍的临床研究

Scientific title:

Clinical study of the intervention of Yiqi Huoxue therapy in sepsis-related cardiac dysfunction

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孟家乐 

研究负责人:

郭涛 

Applicant:

Meng Jiale 

Study leader:

Guo Tao 

申请注册联系人电话:

Applicant telephone:

+86 176 9139 0195

研究负责人电话:

Study leader's
telephone:

+86 138 1390 5939

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

535277049@qq.com

研究负责人电子邮件:

Study leader's E-mail:

saharaicu@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市秦淮区汉中路155号

研究负责人通讯地址:

江苏省南京市秦淮区汉中路155号

Applicant address:

No. 155, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province

Study leader's address:

No. 155, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

210000

研究负责人邮政编码:

Study leader's postcode:

210000

申请人所在单位:

江苏省中医院

Applicant's institution:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

研究负责人所在单位:

江苏省中医院

Affiliation of the Leader:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023NL-051-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京中医药大学附属医院(江苏省中医院)伦理委员会

Name of the ethic committee:

Ethics Committee of the Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Provincial Hospital of Traditional Chinese Medicine).

伦理委员会批准日期:

Date of approved by ethic committee:

2023-04-14 00:00:00

伦理委员会联系人:

王卯

Contact Name of the ethic committee:

Wang Mao

伦理委员会联系地址:

江苏省南京市秦淮区汉中路155号

Contact Address of the ethic committee:

No. 155, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 25 8656 0515

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省中医院

Primary sponsor:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

江苏省南京市秦淮区汉中路155号

Primary sponsor's address:

No. 155, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

china

Province:

jiangsu

City:

单位(医院):

江苏省中医院

具体地址:

江苏省南京市秦淮区汉中路155号

Institution
hospital:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

Address:

No. 155, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province

经费或物资来源:

江苏省中医药管理局

Source(s) of funding:

Jiangsu Administration of Traditional Chinese Medicine

研究疾病:

脓毒症相关心功能障碍  

Target disease:

Sepsis-related cardiac dysfunction

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察益气活血法对脓毒症患者心脏功能的影响,探讨其对脓毒症心脏保护作用的潜在机制。  

Objectives of Study:

To observe the effect of Qi and blood activation on cardiac function in patients with sepsis, and to explore the potential mechanism of its cardioprotective effect on sepsis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 年龄在18岁以下或80岁以上者,或为妊娠期、哺乳期妇女。 2. 基础疾病不可逆或预计48小时内死亡患者,如晚期恶性肿瘤、特重型颅脑损伤等。 3. 过敏体质,或者已知对本药成分过敏者。 4. 放弃抢救,不能进行常规西医及基础生命体征支持治疗的患者。 5. 不符合纳入标准,未按规定用药和治疗,或资料不全等影响疗效或安全性判断者。

Exclusion criteria:

1.Those under the age of 18 or over 80, or pregnant or lactating women. 2.Patients with irreversible underlying diseases or expected death within 48 hours, such as advanced malignant tumors, extremely severe head injury, etc. 3.Allergic constitution, or known to be allergic to the ingredients of this medicine. 4.Patients who have given up rescue and cannot undergo conventional Western medicine and basic vital signs support therapy. 5.Those who do not meet the inclusion criteria, do not use and treat as prescribed, or have incomplete data that affect the efficacy or safety judgment.

研究实施时间:

Study execute time:

From 2023-04-15 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-07-26 00:00:00 To 2025-01-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

60

Group:

Experimental group

Sample size:

干预措施:

益气活血方

干预措施代码:

Intervention:

Yiqi Huoxue Decoction

Intervention code:

组别:

对照组

样本量:

60

Group:

Control group

Sample size:

干预措施:

(0.9%NS100ML)氯化钠注射液

干预措施代码:

Intervention:

(0.9% NS 100ML) Sodium Chloride Injection

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省中医院 

单位级别:

三甲 

Institution
hospital:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

左心室射血分数

指标类型:

主要指标

Outcome:

Left Ventricular Ejection Fractions

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心排血指数

指标类型:

主要指标

Outcome:

Cardiac Index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

缩短分数

指标类型:

主要指标

Outcome:

Fractional shortening

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

左心室舒张末期内径

指标类型:

主要指标

Outcome:

Left Ventricular End-diastolic Dimension

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

E/A

指标类型:

主要指标

Outcome:

E/A

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

E/e'

指标类型:

主要指标

Outcome:

E/e'

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

乳酸

指标类型:

主要指标

Outcome:

Lactate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中心静脉血氧饱和度

指标类型:

主要指标

Outcome:

Central Venous Oxygen Saturation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

动静脉二氧化碳分压差

指标类型:

主要指标

Outcome:

Pv-aCO2

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿量

指标类型:

主要指标

Outcome:

Urine output

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑尿钠肽

指标类型:

次要指标

Outcome:

Brain Natriuretic Peptide

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心肌肌钙蛋白I

指标类型:

次要指标

Outcome:

Cardiac Troponin I

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

内皮细胞特异性分子-1

指标类型:

次要指标

Outcome:

Endocan

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血管内皮生长因子

指标类型:

次要指标

Outcome:

Vascular Endothelial Growth Factor

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

内皮缩血管肽1

指标类型:

次要指标

Outcome:

Endothelin-1

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

可溶性血栓调节蛋白

指标类型:

次要指标

Outcome:

Soluble Thrombomodulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子-α

指标类型:

次要指标

Outcome:

Tumornecrosisfactor-α

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞介素-1β

指标类型:

次要指标

Outcome:

Interleukin-1β

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

补体C5a

指标类型:

次要指标

Outcome:

Complement C5a

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

序惯性器官衰竭评分

指标类型:

次要指标

Outcome:

Sequential organ failure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性生理功能和慢性健康状况评分

指标类型:

次要指标

Outcome:

Acute physiology and chronic health evaluation II

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

机械通气时间

指标类型:

次要指标

Outcome:

Time of mechanical ventilation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU住院时间

指标类型:

次要指标

Outcome:

Length of ICU stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU病死率

指标类型:

次要指标

Outcome:

ICU case fatality rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

28天病死率

指标类型:

次要指标

Outcome:

28-day case fatality rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

附加指标

Outcome:

Blood routine

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿常规

指标类型:

附加指标

Outcome:

Urine routine

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

粪常规

指标类型:

附加指标

Outcome:

Fecal routine

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

附加指标

Outcome:

Liver function

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

附加指标

Outcome:

Kidney function

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由孟家乐采用中心随机化方法。借助 SPSS 统计分析生成随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

The central randomization method was adopted by Meng Jialu. Generate random sequences with SPSS statistical analysis.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

患者不知道分组。

Blinding:

The patient does not know the group.

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用crf表记录数据,excel管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Use CRF tables to record data, excel to manage data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-09-16 08:48:53